Insight Molecular Diagnostics I (IMDX) Fair Value 2026

IMDX · In Vitro & In Vivo Diagnostic Substances ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.9 /10

32 fundamental signals · 10 models active

Value Trap Risk

LOW (30/100)

Quick Summary — As of 2026-07-13, Insight Molecular Diagnostics I (IMDX) trades at $4.59, approximately 144% above CirclFi’s Bayesian DCF fair value of $1.88. QOC: 5.9/10. Value Trap Risk: 30/100 (LOW). 10/13 models active.

Key Facts

Ticker
IMDX
Price
$4.59
Quality Score
5.9/10
Value Trap Risk
30/100
Models Active
10/13
Last Updated
Strength: 10 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($4.59)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $1.88 -59.0%
Earnings Power Value
Medium Conviction
 $1.21 -73.6%
CUCE Ensemble
Low Conviction
 $1.56 -66.1%
First Chicago
Medium Conviction
 $0.81 -82.3%

Unlock the Full Matrix

Access 6 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is Insight Molecular Diagnostics I (IMDX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Insight Molecular Diagnostics I's intrinsic value is estimated at $1.70. Trading at its current price of $4.59, the valuation engine raises significant caution: 9 of 10 models flag downside risk, projecting an average implied return of -62.9%. The most optimistic model, PWERM, places fair value at $5.39 (+17.5%), while Dynamic NAV — the most conservative — estimates $0.72 (-84.3%). This +101.8% gap reflects genuine analytical uncertainty about Insight Molecular Diagnostics I's intrinsic worth.

What Do the Models Say About IMDX?

10 of 13 models are currently active for IMDX. Of these, 1 model suggests upside while 9 models suggest overvaluation. The Bayesian DCF estimates IMDX's intrinsic value at $1.88, implying -59.0% downside from the current price. See which stocks rank higher →

How Does IMDX Rank in In Vitro & In Vivo Diagnostic Substances?

Among 17 In Vitro & In Vivo Diagnostic Substances stocks, IMDX ranks #9 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.

Insight Molecular Diagnostics I operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is IMDX a Value Trap?

CirclFi's Value Trap algorithm assigns IMDX a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Insight Molecular Diagnostics I. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Insight Molecular Diagnostics I earns a quality score of 5.9/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +101.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IMDX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across IMDX's 10 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Insight Molecular Diagnostics I Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar In Vitro & In Vivo Diagnostic Substances Stocks Should You Also Analyze?

8 related In Vitro & In Vivo Diagnostic Substances stocks with 13-model coverage

IDXXIDEXX Laboratories, Inc.QOC 10.0LNTHLantheus Holdings, Inc.QOC 10.0NEOGNeogen CorporationQOC 7.6ICCCImmuCell CorporationQOC 7.2QDELQuidelOrtho CorporationQOC 6.9NTLAIntellia Therapeutics, Inc.QOC 6.2CLDXCelldex Therapeutics, Inc.QOC 6.1VNRXVolitionRX LimitedQOC 6.1

Read investment analysis: IDXX · LNTH · NEOG · ICCC · QDEL

Frequently Asked Questions About Insight Molecular Diagnostics I

What is Insight Molecular Diagnostics I's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Insight Molecular Diagnostics I (IMDX) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $1.88. The Quality of Company score is 5.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IMDX overvalued or undervalued right now?

At $4.59, 1 of 10 active models suggest IMDX may be undervalued, while 9 indicate potential overvaluation. The assessment depends on which methodology best fits Insight Molecular Diagnostics I's business model in In Vitro & In Vivo Diagnostic Substances.

What does a Quality of Company score of 5.9 mean for IMDX?

Insight Molecular Diagnostics I's QOC of 5.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on IMDX?

CirclFi analyzes IMDX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is IMDX a value trap in 2026?

Insight Molecular Diagnostics I's Value Trap score is 30/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on IMDX.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access